ON WEDNESDAY, THE U.S. Food and Drug Administration announced a new policy that could make six experimental peptides more readily available. According to a document released by the HHS, the government will not penalize specialized pharmacies for making and supplying these popular substances to patients with a prescription. The peptides: BPC-157 , epitalon , KPV , MOTS-c , Semax , and TB-500 .

This does not mean these particular peptides have been approved for use by the FDA. In fact, none of them have gone through the rigorous human testing required for FDA drug approval. And the new policy is not intended to be permanent. Instead, it allows temporary access as the FDA decides on a longer-term plan for the six peptides.…